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Background. Histidine-rich glycoprotein (HRG) displays anticoagulant and antifibrinolytic properties in animal models, but its
effects in humans are unclear. We investigated serum HRG levels and their associations with the disease stage and prothrombotic
alterations in lung cancer (LC) patients. Methods. In 148 patients with advanced LC prior to anticancer therapy (87
non-small-cell LC and 61 small-cell LC) versus 100 well-matched controls, we measured HRG levels in association with clot
permeability (Ks), clot turbidimetry (lag phase and maximum absorbance), and clot lysis time (CLT). Results. Compared to
controls, LC patients had 45.9% lower HRG levels with no associations with demographics and comorbidities. Decreased HRG,
defined as the 90th percentile of control values (<52.7μg/ml), was 16 times more common in subjects with than without LC
(OR = 16 4, 95% CI 9.2-23.5, p < 0 01). HRG < 38 μg/ml discriminated stage IIIAB/limited disease from IV/extensive disease (ED)
LC. In LC patients, HRG correlated inversely with CLT (r = −0 41, p < 0 001), but not with other fibrin variables. Among stage
IV/ED LC, HRG correlated significantly with Ks and lag phase (r = 0 28 and r = 0 33, respectively, both p < 0 001). LC patients
with low Ks (10
th percentile of control values) combined with prolonged CLT (90th percentile of control values) had reduced
HRG levels compared to the remainder (p = 0 003). No such observations were noted in controls. Conclusions. Our study is the
first to show that decreased HRG levels occur in advanced LC and are associated with the disease stage and hypofibrinolysis.
1. Introduction
Lung cancer incidence has raised from an infrequent entity in
the year 1912 to one of the most commonly occurring can-
cers over the past century [1]. In 2012, almost 1.82 million
new cases have been diagnosed, representing approximately
12.9% of all cancers worldwide [2]. It is estimated to account
for almost every fifth death (1.59 million deaths per year,
19.4% of the total) [2]. Despite the introduction of new
therapies such as chemotherapy and immunotherapy that
prolong the lives of patients and in some cases make cancer
a chronic disease, lung cancer remains the most prevalent
fatal tumor [2, 3].
Venous thromboembolic disease (VTE) is common in
subjects with active cancer with the prevalence of 20% in
this disease [4]. Approximately 3% of lung cancer patients
experience a VTE episode within two years after diagnosis,
which is associated with a higher mortality for both
non-small-cell lung carcinoma (NSCLC) and small-cell
lung carcinoma (SCLC) [5]. Prothrombotic mechanisms
resulting in VTE occurrence among lung cancer patients
include enhanced expression and release of tissue factor,
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higher levels of thrombin-antithrombin complexes and
plasmin-alpha 1-antiplasmin complexes, increase in plate-
let count, and elevated levels of procoagulant factors such
as lupus anticoagulant, anticardiolipin antibodies to factor
VIII, interleukin-6, and tumor necrosis factors [6].
Plasma fibrin clots are formed as ultimate products of
thrombin-mediated conversion of fibrinogen into fibrin.
Genetic and environmental factors affect the formation of
compact, highly branched networks with thin fibers resistant
to fibrinolysis [7, 8]. Fibrin clot properties are unfavorably
altered by cigarette smoking [9], a well-established risk factor
for nearly 90% cases of lung cancer [10]. Among patients
with malignancy, subjects with digestive tract cancer [11]
and multiple myeloma [12] were characterized by a pro-
thrombotic clot phenotype. There is evidence for pathologi-
cal clot microstructure with changes of physical properties,
including higher fractal dimension in patients with extensive
than those with localized lung cancer [13].
Since its discovery in 1972 [14], histidine-rich glyco-
protein (HRG), an abundant plasma protein produced in
the liver and circulating at a concentration of 100–
150μg/ml [15], remains poorly characterized in terms of
its role in human pathophysiology. Plasma HRG concentra-
tions increase with age but decrease in acute inflammation,
chronic autoimmune diseases, advanced liver cirrhosis, after
renal transplantation, in asthma and chronic obstructive pul-
monary disease treated with corticosteroids, and in acquired
immune deficiency syndrome [15, 16]. Reduced HRG levels
have been found in patients with ovarian cancer and hepato-
cellular carcinoma [17, 18]. HRG binds to heparin, which
prevents the formation of heparin-antithrombin complexes
and results in inhibition of the antithrombin activity [19]. It
is estimated that nearly 50% of plasminogen circulates bound
to HRG, which reduces plasminogen available to bind fibrin
[19, 20]. Moreover, HRG can be incorporated to fibrin clots
and its presence causes the formation of thinner fibrils as
demonstrated in a purified system [20]. HRG-deficient mice,
compared to control, showed higher spontaneous fibrinolytic
activity but shorter prothrombin and bleeding time, indicat-
ing both prothrombotic and antifibrinolytic properties [21].
A role of HRG in human hemostasis is unclear. There is
evidence for an active involvement of HRG in cancer
largely by displaying both pro- and antiangiogenic properties
[22–25]. Moreover, HRG by promoting tumor-associated
macrophage polarization into an antitumor phenotype
[24, 25] may result in tumor growth inhibition and it is a
possible mechanism of cancer progression. Available data
on HRG in cancer patients is inconsistent [26–28]. To our
knowledge, no reports on HRG in lung cancer and its role
in prothrombotic alterations have been published until
now. Based on the available data, we hypothesized that
HRG levels are reduced in advanced lung cancer in associa-
tion with the disease severity and they contribute to unfavor-
able fibrin clot properties.
2. Materials and Methods
2.1. Patients. From May to September 2014, 148 consecutive
adult patients with advanced lung cancer prior to anticancer
treatment were recruited at the John Paul II Hospital in
Cracow, Poland. This cohort was part of the study population
reported previously in detail [29]. Briefly, lung cancer was
confirmed and classified with the applicable histological
classification of lung cancer according to the World Health
Organization with the International Association for the
Study of Lung Cancer modification for adenocarcinoma.
Cancer stage was determined according to the American
Joint Committee on Cancer 7th edition staging scheme.
Controls (n = 100) matched for age, sex, and cardiovascular
risk were recruited using the same screening protocol and
included members of the hospital personnel and their rela-
tives. The exclusion criteria for both groups were as follows:
any infections, glomerular filtration rate < 60ml/min, hypo-
or hyperthyroidism, any acute vascular events, acute venous
thromboembolism, and current anticoagulant therapy except
for prophylactic doses of low-molecular-weight heparin
administered for the last time 12 h or more prior to the
sample collection.
The research has been complied with all the relevant
national regulations and institutional policies and in accor-
dance with the tenets of the Helsinki Declaration and has
been approved by the local ethical committee. A written
informed consent was obtained from each participant.
2.2. Laboratory Investigations. Fasting blood samples were
drawn from an antecubital vein with minimal stasis between
8:00 and 11:00 AM. Routine laboratory techniques were
applied to determine blood cell count, creatinine, and
D-dimer. Fibrinogen was determined using the Clauss
method. Plasminogen was measured by a chromogenic assay
(STA Stachrom; Diagnostica Stago, Asnieres, France). HRG
was measured using an ELISA according to the manufac-
turer’s instruction (Cusabio Technologies, US).
2.3. Plasma Fibrin Clot Analysis. In citrated plasma (vol/vol,
9 : 1 of 3.2% sodium citrate), the following variables describ-
ing a plasma clot formation, structure, and lysability were
determined in duplicate by technicians blinded to the origin
of the samples (intra-assay and interassay coefficients of
variation, 5% to 7%). Details of the methodology used were
presented previously [30].
2.3.1. Clot Permeability. Permeation of plasma fibrin clots
was determined as described [31]. Briefly, 20mM calcium
chloride and 1U/ml human thrombin (Sigma-Aldrich, St.
Louis, MO, USA) were added to citrated plasma. Tubes
containing the clots were connected to a reservoir of a
Tris-buffered saline (TBS; 0.01M Tris, 0.1M NaCl, pH7.4),
and its volume flowing through the gels was measured. A
permeation coefficient (Ks), which indicates the pore size,
was calculated from the following equation: Ks =Q × L × η/
t × A × Δp, where Q is the flow rate in time t, L is the length
of a fibrin gel, η is the viscosity of liquid (in poise), t is
percolating time, A is the cross-sectional area (in cm2),
and Δp is a differential pressure (in dyne/cm2).
2.3.2. Turbidity Measurements. Plasma citrated samples were
mixed at a ratio of 2 : 1 with a TBS containing 0.6U/ml
human thrombin (Sigma-Aldrich) and 50mM CaCl2 to
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initiate polymerization. Absorbance was read at 405nm with
a Perkin-Elmer Lambda 4B spectrophotometer (Molecular
Devices). The lag phase of the turbidity curve, which
reflects the time required for initial protofibril formation,
and maximum absorbance at the plateau phase (ΔAbs),
indicating the number of protofibrils per fiber, were
recorded [31].
2.3.3. Clot Lysis Assay. Clot lysis time (CLT) was measured as
described previously [31]. Briefly, to 75μl of citrated plasma
we added TF (dilution 105 times; Innovin, Dade Behring,
Deerfield, IL, USA), CaCl2 (final concentration, 17mM),
tissue plasminogen activator (tPA, final concentration,
30U/ml; Boehringer Ingelheim, Ingelheim, Germany), and
phospholipid vesicles [32] (final concentration, 10mM).
HEPES buffer was added to make a total volume of 150μl.
2.4. Statistical Analysis. Data management was performed
with STATISTICA 10.0 software (StatSoft Inc. 2011, Tulsa,
OK, USA). Normal distribution for continuous variables
was checked using the Shapiro-Wilk statistics. Continuous
variables were presented as mean ± SD for normally distrib-
uted variables and as a median and interquartile range for
nonnormally distributed variables. Proportional variables
were compared by χ2 test and Student’s t-test while continu-
ous variables by Mann-Whitney U-test (Kruskal-Wallis and
multiple repetition tests), as appropriate. Pearson’s rank
correlation coefficient was used to evaluate an association
between two variables. To test the relationship between
continuous variables, a univariate linear regression model
was used. Because HRG had a skewed normal distribution,
a 10 log-transformed data was entered for a better fit the
model. Other variables were calculated on the original scale.
Independent determinants of HRG were established in a
multiple regression model, built by a forward stepwise
selection procedure, verified by Snedecore’s F statistics, with
F > 1. The R2 was used as a measure of the variance.
Log-linear analysis and unconditional multivariate logistic
regression were performed to make adjustments for categor-
ical variables (age, body mass index, and gender) [30]. To
calculate odds ratios (ORs) with 95% CIs, Ks, CLT, and
HRG values were divided using the value of 90th percentile
in controls as a cut-off point. The best cut-off value that
maximizes sensitivity and specificity and differentiates lung
cancer patients from control subjects was calculated by using
the receiver operating characteristic (ROC) curve. The sig-
nificance level was set at p < 0 05.
3. Results
3.1. Patient Characteristics.A final analysis included 148 lung
cancer patients and 100 matched control subjects (Table 1).
There were 58 (39.19%) subjects diagnosed with SCLC,
including 33 patients with limited disease and 25 patients
with extensive disease, and 90 (60.81%) subjects with NSCLC
(among them 24 with IIIAB stage/locally advanced inopera-
tive neoplasm and 66 with IV stage/metastatic disease). As
expected the lung cancer patients had lower BMI and were
more often smokers (79 vs. 10; Table 1). They also had higher
white blood cells (WBC), lower hemoglobin, and higher
platelet count (Table 1). The cancer group had elevated
D-dimer and fibrinogen. Among fibrin clot variables, low-
ered Ks (-26.52%), prolonged lag phase (+8.24%), increased
ΔAbs (+6.25%), and longer CLT (+31.13%) were detected
in lung cancer patients. The study groups did not differ
in plasminogen levels.
3.2. HRG Serum Level Associations. Lung cancer patients had
45.87% lower HRG level compared to control subjects
(Figure 1). Serum HRG showed no associations with demo-
graphic variables. Comparing histological subtypes of LC in
the studied cohort, we observed that patients diagnosed with
adenocarcinoma (n = 41) had lowered HRG (median, 32
(28-40)μg/ml vs. 39 (32-44)μg/ml, p = 0 002). Reduced
HRG levels were detected in patients with metastases
(n = 101, 33 8 ± 7 6 vs. 41 4 ± 7 8μg/ml, p = 0 044). Meta-
static cancer was also associated with prolonged CLT
(>105min, OR = 2 09, 95% CI (1.18-3.73), p = 0 01), but
not with other fibrin variables.
In the lung cancer group, HRG was inversely corre-
lated with D-dimer (r = −0 37, p < 0 001) and fibrinogen
(r = −0 18, p < 0 001), while it was positively correlated with
lag phase (r = 0 20, p < 0 001). Ks and ΔAbs showed no
associations with HRG in cancer patients, however CLT
was inversely correlated with HRG (r = −0 38, p < 0 001).
In the stage IIIAB/LD lung cancer patients, lowered HRG
was associated with longer CLT (r = −0 41, p < 0 001), while
in more advanced stage IV/ED, reduced HRG was associ-
ated with higher D-dimer (r = −0 35, p < 0 001), shorter
lag phase (r = 0 33, p < 0 001), decreased Ks (r = 0 28, p <
0 001), and prolonged CLT (r = −0 5, p < 0 001). No such
correlations were detected for HRG and fibrinogen or
plasminogen.
Low HRG levels defined using the 90th percentile of
control values (i.e., 57.2μg/ml) observed in 143 (94.08%)
lung cancer patients were detected in all patients diagnosed
with stage IV/ED lung cancer. Metastatic stage IV/ED lung
cancer patients had significantly decreased HRG compared
to locally advanced lung cancer (stage IIIAB/LD) subjects
(p < 0 0001, Figure 1). HRG cut-off levels which discrimi-
nate lung cancer patients from healthy subjects and stage
IIIAB/LD from stage IV/ED lung cancer were below
49.2μg/ml (sensitivity, 98% and specificity, 90%) and below
38μg/ml (sensitivity, 80% and specificity, 70%) (Figure 2),
respectively. HRG below 38μg/ml was associated with
stage IV/ED lung cancer (OR = 3 07, 95% CI 2.08-4.54,
p < 0 01).
A multiple logistic regression analysis showed associa-
tions between HRG levels and Ks as well as CLT in lung
cancer patients (Table 2), also after adjustment for aspirin
use (data not shown). In the combined analysis, compact
fibrin clots (1st quartile of control values of Ks) and hypo-
fibrinolysis (4th quartile of control values of CLT) were
more often found in subjects with lung cancer (OR = 3 08,
95% CI 2.29-4.14 and OR = 2 95, 95% CI 2.2-3.95, respec-
tively). Among patients who had HRG below 52.7μg/ml,
62.24% of them formed dense and poorly lysable fibrin
clots (Figure 3).
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4. Discussion
The present study is the first to show associations between
unfavorably altered fibrin clot properties and serum HRG
level in advanced lung cancer patients. Moreover, we
observed lower HRG levels in this patient group in associa-
tion with more advanced cancer stage. Lower HRG was
linked to reduced clot permeability and impaired susceptibil-
ity to lysis, which might contribute to thromboembolic
events in cancer patients [33]. The study increases the
current knowledge on the role of HRG in lung cancer by
showing that the lower the HRG, the more advanced the
disease stage and the more altered the clot features. Existing
evidence indicates that HRG represents an adaptor protein
with the potential to modulate immune, vascular, and coagu-
lation systems, which are involved in cancer development. In
the tumor environment, HRG promotes tumor-associated
macrophage polarization into an antitumor (M1) phenotype
[24, 25]. The presence of HRG normalizes tumor vasculature,
allowing cytotoxic T-lymphocytes, natural killers, and den-
dritic cells to infiltrate into its microenvironment [24, 25],
resulting in tumor growth inhibition. HRG released from
platelets have been shown to promote angiogenesis in cancer
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Figure 1: Distribution of histidine-rich glycoprotein (HRG) serum
levels in controls and lung cancer patients with stage IV/extensive
disease and locally advanced inoperative stage IIIAB/limited
disease. Data are presented as median, interquartile range, and
maximum and minimum values. Numbers on the graph represent
p values in comparison to control and between lung cancer patient
groups. LD: limited disease; ED: extensive disease.
Table 1: Demographic, clinical, and laboratory characteristics of lung cancer patients and control subjects.
Variable Lung cancer patients (n = 148) Control subjects (n = 100) p value
Age (years) 65 (46-82) 63 (43-81) 0.49
Male, n (%) 30 (20.3) 20 (20.0) 0.08
Body mass index (kg/m2) 25.0 (14.6-40.6) 26.9 (19.9-36.2) <0.0001
Clinical features
Current smoking, n (%) 53 (35.8) 10 (10.0) <0.0001
Arterial hypertension, n (%) 48 (32.4) 55 (55.0) 0.3
Diabetes mellitus, n (%) 12 (8.1) 7 (7.0) 0.19
Previous stroke, n (%) 4 (2.7) 8 (8.0) 0.09
Medications
Statin, n (%) 26 (17.6) 42 (42.0) 0.004
Aspirin, n (%) 25 (16.9) 38 (38.0) 0.005
Laboratory investigations
WBC (103/μl) 9.2 (8.4-10.0) 6.0 (5.8-6.2) <0.0001
Hemoglobin (g/dl) 12.8 (12.6-13.0) 13.9 (13.7-14.1) <0.0001
Hematocrit (%) 39.2 (38.7-39.7) 41.3 (40.9-41.8) <0.0001
Platelets (103/μl) 309 (298-320) 237 (229-245) <0.0001
Creatinine (μM) 74 (72-76) 68 (66-69) 0.028
D-dimer (ng/ml) 477 (402-552) 225 (217-233) <0.0001
Fibrinogen (g/l) 3.16 (3.10-3.25) 2.47 (2.24-3.10) <0.0001
Plasminogen (%) 102.8 (101.0-104.6) 104.8 (102.9-106.6) 0.79
HRG (μg/ml) 37.0 (36.2-37.9) 68.4 (66.5-70.2) <0.0001
Fibrin clot characteristics
K s (10
-9 cm2) 6.65 (6.54-6.76) 9.05 (8.84-9.26) <0.0001
Lag phase (s) 39.0 (38.6-39.4) 42.5 (40-46) <0.0001
ΔAbs (405 nm) 0.85 (0.84-0.86) 0.80 (0.79-0.81) <0.0001
Clot lysis time (min) 99.0 (97.2-100.8) 75.5 (73.7-77.3) <0.0001
Data are given as number (percentage),mean ± SD, or median (interquartile range). Abbreviations: WBC: white blood cells; HRG: histidine-rich glycoprotein;
Ks: fibrin clot permeability coefficient.
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by interfering with thrombospondin 1 and thrombospondin
receptor CD36-mediated antiangiogenic signaling [22, 23].
Other studies have postulated an antiangiogenic activity
of HRG. In mice, HRG deficiency was associated with
reduced expression of antiangiogenic chemokines such as
chemokine C-X-C motif ligand 10 and chemokine C-X-C
motif ligand 11 and also decreased vessel coverage and
perfusions [24]. In HRG-treated mice, tumor vascularization
was inhibited [25]. Proteomics study using isobaric tagging
and LC-MS/MS analysis revealed a significant reduction in
serum HRG associated with progression of hepatitis B
virus-related hepatocellular carcinoma [18]. Wang et al.
observed downregulation of serum HRG precursor by
LC-MS/MS in patients with atypical endometrial hyperplasia
compared to normal donor controls, indicating that lower
HRG levels lead to endometrial cancer progression [27].
Wu et al. [17] assessed ovarian cancer patients and showed
decreased HRG levels in patients with stage I/II as well as
with stage III ovarian cancer compared to healthy controls
[17]. HRG levels may also be increased in some malignancies
as reported by Matboli et al. who observed higher HRG levels
in breast cancer (median, 17.1mg/dl) compared to benign
breast lesions (median, 1.56mg/dl) and the control (median,
1.1mg/dl) group [26]. Ahmed et al. [28] have observed in
acute lymphoblastic leukemia that both HRG serum levels
and protein RNA expression decreased during the leukemia
treatment. Taken together, the present study shows that
advanced lung cancer is associated with decreased HRG
levels, which appears to be a common feature in most
advanced cancers. A novel observation is that prothrombotic
alterations are related to this decrease.
This study has several limitations. First, the sample size
was limited and HRG levels were measured at a single time
point. Second, we did not measure several potential fibrin
clot modifiers including homocysteine, which were beyond
the scope of the study. Third, the correlations demonstrated
in the present study may not necessarily mean cause-effect
relationships. Fourth, the current data cannot be necessarily
extrapolated to patients with stages I and II lung cancer.
Finally, in vitro experiments to better characterize the
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Figure 2: Receiver operating characteristic (ROC) curve for serum levels of histidine-rich glycoprotein (HRG) to discriminate between
lung cancer patients and healthy subjects (a) and between IIIAB/limited disease and IV/extensive disease lung cancer (b). The blue line
represents serum HRG level and the red line represents the reference line. The best cut-off point of HRG at 49.2 μg/ml (a) and
38μg/ml (b) is marked, P < 0 0001.
Table 2: Determinants of histidine-rich glycoprotein serum levels
in lung cancer patients.
Simple regression Multiple regression
β p β p R2
Lung cancer patients
Ks 0.09 0.27 -0.13
<0.001 0.19CLT -0.41 <0.001 -0.42
Fibrinogen -0.18 0.03 -0.15
Stage IIIAB/LD lung
cancer patients
Ks -0.09 0.71 -0.09
0.014 0.17CLT -0.41 0.001 -0.44
Fibrinogen -0.09 0.48 -0.00
Stage IV/ED lung
cancer patients
Ks 0.28 0.008 0.07
<0.001 0.26CLT -0.5 <0.001 -0.46
Fibrinogen -0.18 0.09 -0.06
Ks: fibrin clot permeability coefficient; CLT: clot lysis time; LD: limited
disease; ED: extensive disease.
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function of HRG in lung cancer patients, including HRG
binding to heparin and fibrin clots [34–36], should be per-
formed in the future. It is also worth investigating whether
HRG levels and fibrin properties in lung cancer patients are
associated with inflammation and cellular senescence [37].
5. Conclusions
The current study shows that decreased HRG levels occur in
advanced lung cancer and are associated with the disease
stage and prothrombotic plasma clot characteristics, includ-
ing faster formation of more compact clots and impaired
susceptibility to lysis. Clinical relevance of these findings
needs further investigation.
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range, and maximum/minimum values. p = 0 003. Ks: fibrin clot
permeability coefficient; CLT: clot lysis time.
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